Cahaba Wealth Management Inc. Decreases Stake in HCA Healthcare, Inc. (NYSE:HCA)

Cahaba Wealth Management Inc. lowered its position in HCA Healthcare, Inc. (NYSE:HCAFree Report) by 4.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,476 shares of the company’s stock after selling 240 shares during the quarter. Cahaba Wealth Management Inc.’s holdings in HCA Healthcare were worth $1,482,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. State Street Corp raised its holdings in HCA Healthcare by 1.7% during the second quarter. State Street Corp now owns 8,975,423 shares of the company’s stock worth $2,723,861,000 after purchasing an additional 149,750 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of HCA Healthcare by 1.7% in the 1st quarter. Geode Capital Management LLC now owns 3,812,961 shares of the company’s stock valued at $1,002,773,000 after acquiring an additional 64,029 shares during the period. Royal Bank of Canada increased its holdings in shares of HCA Healthcare by 102.0% in the 2nd quarter. Royal Bank of Canada now owns 3,650,988 shares of the company’s stock valued at $1,108,001,000 after acquiring an additional 1,843,887 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in shares of HCA Healthcare by 14.1% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,800,847 shares of the company’s stock valued at $701,948,000 after acquiring an additional 347,177 shares during the period. Finally, Norges Bank acquired a new position in shares of HCA Healthcare in the 4th quarter valued at $547,104,000. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Price Performance

HCA stock traded down $0.76 during trading on Tuesday, hitting $329.35. The stock had a trading volume of 904,576 shares, compared to its average volume of 1,082,828. HCA Healthcare, Inc. has a 1-year low of $215.96 and a 1-year high of $334.49. The company’s 50 day moving average price is $313.78 and its two-hundred day moving average price is $274.88. The company has a debt-to-equity ratio of 35.07, a quick ratio of 1.02 and a current ratio of 1.18. The stock has a market cap of $87.11 billion, a price-to-earnings ratio of 17.35, a price-to-earnings-growth ratio of 1.67 and a beta of 1.65.

HCA Healthcare (NYSE:HCAGet Free Report) last issued its quarterly earnings results on Tuesday, January 30th. The company reported $5.90 EPS for the quarter, topping the consensus estimate of $5.05 by $0.85. The firm had revenue of $17.30 billion during the quarter, compared to analyst estimates of $16.51 billion. HCA Healthcare had a net margin of 8.07% and a return on equity of 996.30%. HCA Healthcare’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.64 earnings per share. On average, sell-side analysts forecast that HCA Healthcare, Inc. will post 20.49 EPS for the current fiscal year.

HCA Healthcare Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 15th were paid a dividend of $0.66 per share. This is an increase from HCA Healthcare’s previous quarterly dividend of $0.60. This represents a $2.64 annualized dividend and a yield of 0.80%. The ex-dividend date was Thursday, March 14th. HCA Healthcare’s payout ratio is currently 13.91%.

HCA Healthcare announced that its board has initiated a share repurchase plan on Tuesday, January 30th that authorizes the company to repurchase $6.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 7.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Raymond James lifted their target price on shares of HCA Healthcare from $300.00 to $330.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Sanford C. Bernstein lowered shares of HCA Healthcare from an “outperform” rating to a “market perform” rating and lifted their price objective for the company from $277.00 to $301.00 in a research report on Thursday, January 4th. StockNews.com lowered shares of HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 15th. The Goldman Sachs Group lowered shares of HCA Healthcare from a “buy” rating to a “neutral” rating and set a $271.00 price objective on the stock. in a research report on Monday, December 11th. Finally, Truist Financial boosted their target price on shares of HCA Healthcare from $320.00 to $345.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $311.47.

Get Our Latest Stock Report on HCA Healthcare

Insider Activity

In other HCA Healthcare news, SVP Kathleen M. Whalen sold 4,262 shares of the firm’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $306.21, for a total value of $1,305,067.02. Following the transaction, the senior vice president now directly owns 10,250 shares of the company’s stock, valued at $3,138,652.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other HCA Healthcare news, SVP Kathleen M. Whalen sold 4,262 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $306.21, for a total value of $1,305,067.02. Following the completion of the sale, the senior vice president now owns 10,250 shares of the company’s stock, valued at $3,138,652.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Chad J. Wasserman sold 876 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $330.25, for a total transaction of $289,299.00. Following the completion of the sale, the senior vice president now directly owns 1,576 shares of the company’s stock, valued at approximately $520,474. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,840 shares of company stock valued at $4,588,869. Company insiders own 1.70% of the company’s stock.

HCA Healthcare Profile

(Free Report)

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Featured Stories

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCAFree Report).

Institutional Ownership by Quarter for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.